Go to Contents Go to Navigation

76 coronavirus patients administered remdesivir in S. Korea

All News 14:42 July 21, 2020

SEOUL, July 21 (Yonhap) -- South Korea so far has administered remdesivir, an experimental drug conventionally used for Ebola, to 76 coronavirus patients in critical condition here, health authorities said Tuesday.

The medication developed by U.S. pharmaceutical giant Gilead Sciences Inc. started to be supplied to treat COVID-19 patients here earlier this month, according to the Korea Centers for Disease Control and Prevention (KCDC).

Coronavirus patients who need oxygen treatment, such as extracorporeal membrane oxygenation (ECMO), have been administered the drug in 27 hospitals across the country, the KCDC said.

This undated file photo shows remdesivir, an experimental drug conventionally used for Ebola by U.S. pharmaceutical giant Gilead Sciences Inc. (Yonhap)

South Korea's drug safety watchdog approved the use of remdesivir as a treatment drug for the new coronavirus in June, allowing for the drug's special importation.

The first batch of the antiviral drug was donated by Gilead Science. The KCDC plans to begin talks to purchase more, with details of the imported amount and price not to be disclosed.

Gilead Sciences earlier announced it will provide remdesivir at US$390 per vial for direct purchase by the United States and other developed countries.

COVID-19 patients here do not pay for the drug, as the country covers the cost of treating the highly infectious disease under the related law.

Coronavirus patients are given six vials of remdesivir over five days, which amounts to $2,340 per patient for a typical regimen. If necessary, the drug can be administered for another five days.

The country identified 45 new cases on Tuesday, raising the total caseload to 13,816, according to the KCDC. Of the newly added cases, 20 were local infections.

khj@yna.co.kr
(END)

Keywords
HOME TOP
Send Feedback
How can we improve?
Thanks for your feedback!